Methacrylamide-Rich Methacrylate Copolymer for Drug Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methacrylic copolymers used in pharmaceutical and nutraceutical compositions face challenges in providing stable, easily processable, and improved dosing characteristics, necessitating the development of novel polymers with enhanced properties.
Innovation Solution
A methacrylic copolymer comprising at least 34 wt.% units derived from methacrylamide, particularly dimethylaminopropyl methacrylamide, is synthesized through free radical polymerization, offering improved stability and processing ease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing methacrylic copolymers are used in pharmaceutical compositions, then drug release properties can be modified, but stability and processing characteristics are insufficient
Solution Approach 1:
The patent changes the compositional parameters of the copolymer by specifying a minimum content of 34 wt.% methacrylamide units and defining specific ratios of alkyl methacrylate units, thereby achieving improved stability and processing characteristics while maintaining drug release modification capabilities
Solution Approach 2:
The invention creates a composite copolymer structure combining multiple monomer units (alkyl methacrylate and methacrylamide) in specific proportions, where the synergistic interaction between different units provides both enhanced stability and improved processing ease that neither unit could achieve alone
2Reliability
If existing methacrylic copolymers are used, then drug release properties can be controlled, but dosing characteristics are not improved
Solution Approach 1:
The patent optimizes dosing characteristics by adjusting the compositional parameters of the copolymer, specifically setting the methacrylamide unit content at ≥34 wt.% and defining precise alkyl methacrylate unit ratios, which enhances dosing precision while maintaining broad applicability in pharmaceutical formulations
3Reliability
If higher content of methacrylamide units is used, then stability and processing ease are improved, but polymerization complexity increases
Solution Approach 1:
The patent achieves high stability with ≥34 wt.% methacrylamide units by optimizing polymerization parameters including initiator selection (water-soluble initiators), temperature control (50-80°C), and monomer ratio specifications, which simplifies the overall process despite the high functional monomer content
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel copolymer enhances the stability and processing efficiency of pharmaceutical and nutraceutical compositions, providing improved dosing characteristics and solubility of active ingredients.
Implementation Method 1
improved dosing characteristics and solubility of active ingredients
Implementation Method 2
enhances the stability and processing efficiency of pharmaceutical and nutraceutical compositions
Data Source
AI summary
A novel methacrylic copolymer contains units derived from at least one alkyl methacrylate and methacrylamide. The units derived from methacrylamide are present in at least 34 wt.-%, based on the total weight of the methacrylic copolymer. A method can be used for preparing these novel methacylic copolymers. Pharmaceutical compositions, nutraceutical compositions, coated pharmaceutical or nutraceutical dosage forms, as well as nano- or microparticles can contain the methacrylic copolymer. The methacrylic copolymer can be used as a coating, as a carrier, and as a matrix for an amorphous solid dispersion.